Product Code: PHM075B
The global market for blood-brain barrier (BBB) technology for therapeutics
reached $21.8 million in 2013. This market is expected to grow from $38.7
million in 2014 to $471.5 million in 2019, a compound annual growth rate
(CAGR) of 64.9% from 2014 through 2019.
This report provides:
- An overview of the global market for blood-brain barrier (BBB)
therapeutics and technologies.
- Analyses of global market trends, with data from 2013, estimates for 2014,
and projections of CAGRs through 2019.
- A look at how blood-brain barrier technology will impact the
pharmaceutical market.
- Information on applications, market values, growth potential, and
significant trends for BBB technology.
- Knowledge most pertinent to biotechnology and pharmaceutical industries
and related life science, analytics, drug discovery, and diagnostic test
manufacturing companies.
- Profiles of leading companies in the industry.
REPORT SCOPE
SCOPE OF REPORT
The scope of this study encompasses companies that develop technologies to
enable the crossing of the BBB and drug development, in which a quality of the
development is enabling the crossing of the BBB, where passage was previously
impossible often due to size. BCC Research analyzes each technology,
determines its current market status, examines its impact on future markets,
and presents forecasts of growth over the next five years. Technological
issues, including the latest trends, are discussed.
ANALYST'S CREDENTIALS
Kim Lawson is a graduate of Mount Holyoke College with a degree in English
Literature. She acquired experience as a healthcare journalist, including
working for John Wiley & Sons as a print reporter, before serving as a
research analyst in a small market research firm that focused on
pharmaceuticals and biotechnology in the Research Triangle Park area of North
Carolina. Before joining that firm, Kim published two reports on emerging and
established diagnostics and therapeutics for benign and cancerous breast
disease.
Table of Contents
CHAPTER 1 INTRODUCTION
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THIS STUDY
- SCOPE OF REPORT
- INTENDED AUDIENCE
- METHODOLOGY
- INFORMATION SOURCES
- ANALYST'S CREDENTIALS
- RELATED BCC RESEARCH REPORTS
- BCC RESEARCH WEBSITE
- DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
- SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH
2019 ($ MILLIONS)
- SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
2012-2019 ($ MILLIONS)
- EMERGING BBB TECHNOLOGY MARKET
- KEY DRIVERS
- KEY CHALLENGES
CHAPTER 3 OVERVIEW
- MAJOR TRENDS
- TODAY'S PHARMA MARKET
- TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH 2017
($ BILLIONS)
- FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017
(PERCENT OF GLOBAL SALES)
- FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO THE
U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS)
- FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION,
2019* ($ MILLIONS)
- FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY THERAPEUTIC
AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS)
- FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN
CLINICAL DEVELOPMENT, 2019* (%)
- BIOLOGICS
- TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY,
2013
- GENERICS SIGNAL NEED FOR INNOVATION
- NEUROFOCUSING IN THE PHARMA INDUSTRY
- FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS)
- TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019
(NUMBER OF UNITS COMMERCIALIZED)
- TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE CNS
INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION)
- TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
- EMERGING BBB TECHNOLOGY MARKET
- BRIEF HISTORY OF BBB
- BLOOD BRAIN BARRIER DEFINED
- BBB COMPONENTS
- Pericytes
- Tight Junctions
- Lipid Barrier
- Enzymatic Barrier
- Efflux Pumps
- BBB ILLUSTRATED
- FIGURE 7 PARTS OF THE BBB
- MAIN AREAS OF THE BRAIN
- FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS
- TREATING DISEASE AND THE BBB
- MENINGITIS
- MULTIPLE SCLEROSIS (MS)
- ENCEPHALITIS 3
- ALZHEIMER'S DISEASE (AD)
- PARKINSON'S DISEASE (PD)
- BBB TECHNOLOGY CLASSIFICATION
- MOST COMMON BBB TECHNOLOGY
- CHALLENGES WITH THE MOST COMMON TECHNOLOGY USED
- TRANSPORT CONSIDERATIONS
- BBB TECHNOLOGY DETAILED
- Chemical Transport Systems
- Biological Carrier or Transport Systems
- Physical Force (Energetic) Opening Through Sound Waves (Targeted
Ultrasound)
- Enhancing Biological Transport System Techniques
- FIGURE 9 METHODS OF CROSSING THE BBB
- Nanoparticles and Liposomes
- Nanoparticles
- TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY
- Challenges with Nanoparticles
- Liposomes
- PATENTS AND INTELLECTUAL PROTECTION
- TABLE 7 KEY BBB TECHNOLOGY PATENTS
- ArmaGen's Patent Estate
- Life After Patenting
- TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE
YEARS ENDING 2013
- BBB TECHNOLOGY MARKET: PRESENT AND FUTURE
- TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH
PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS)
- FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE,
2014* (% OF INDUSTRY)
- FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE
COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET)
- TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS)
- FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS)
- TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL METHOD
- TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING DEALS
OR LARGE INVESTMENT WITH LEAD DISEASE TARGET
- Genzyme Innovates and Sells Technology to Pharmidex
- DRUG DEVELOPMENT IN THE CNS
- Multiple Models Must Be Used
- BBB Is Its Own Site of Investigation
- Understanding Interactions and Brain Areas as Distinct
- TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB TECHNOLOGIES
- What Values Are Best
- TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL
EFFECTS
- PROMISING RESEARCH
- PROMISING CNS DRUGS THAT ARE LATER STAGE IN THE DEVELOPMENT PIPELINE FOR
POTENTIAL USE WITH BBB TECHNOLOGY
- Brain Cancer
- TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019
- Anxiety
- TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019
- Dementia
- TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019
- Parkinson's disease
- TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019
- Depression
- TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019
- Personality/Psychiatric Disorders (Schizophrenia/bipolar)
- TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019
- Spinal Cord Injury
- TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019
- Addiction Disorders
- TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019
- Attention Deficit Hyperactivity Disorder (ADHD)
- TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER,
THROUGH 2019
- Sleep Disorders
- TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019
CHAPTER 4 COMPANY PROFILES
- ABLYNX
- ADENIOS
- ANGIOCHEM
- ARMAGEN TECHNOLOGIES
- BIOASIS TECHNOLOGIES
- BRISTOL-MYERS SQUIBB
- CAPSULUTION PHARMA
- DAINIPPON SUMITOMO PHARMA
- ELI LILLY AND COMPANY
- EUTHYMICS BIOSCIENCE
- FABRE-KRAMER PHARMACEUTICALS
- FLOCEL
- FORUM PHARMACEUTICALS
- GENZYME
- INSIGHTEC
- INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS)
- ISIS INNOVATION
- JANSSEN PHARMACEUTICA
- H LUNDBECK
- MEDGENESIS THERAPEUTIX (BIOVAIL LAB)
- MEDIMMUNE
- MEDINVENT
- NANOMERICS
- NEUROVIVE PHARMACEUTICAL
- NEUREN PHARMACEUTICALS
- NSGENE
- OPTINOSE
- OSSIANIX
- OTSUKA AMERICA PHARMACEUTICAL
- PROTHENA CORP
- PROTHERAGEN
- PFIZER
- PHARMACO-CELL
- PHARMIDEX
- RAPTOR PHARMACEUTICAL
- ROCHE
- ROYALTY PHARMA
- SHIRE
- SANERON CCEL THERAPEUTICS
- SOLVO BIOTECHNOLOGY
- SOVICELL
- TEVA PHARMACEUTICAL INDUSTRIES
- TO-BBB TECHNOLOGIES
- TTY BIOPHARM
- UCB
- VECT-HORUS
- XENOPORT
- XIGEN
LIST OF TABLES
- SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH
2019 ($ MILLIONS)
- TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH 2017
($ BILLIONS)
- TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
- TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019
(NUMBER OF UNITS COMMERCIALIZED)
- TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE CNS
INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION)
- TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
- TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY
- TABLE 7 KEY BBB TECHNOLOGY PATENTS
- TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS
ENDING 2013
- TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH
PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS)
- TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019
(NUMBER OF UNITS)
- TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL METHOD
- TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING DEALS
OR LARGE INVESTMENT WITH LEAD DISEASE TARGET
- TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB TECHNOLOGIES
- TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL EFFECTS
- TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019
- TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019
- TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019
- TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019
- TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019
- TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019
- TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019
- TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019
- TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER,
THROUGH 2019
- TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019
LIST OF FIGURES
- SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
2012-2019 ($ MILLIONS)
- FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017
(PERCENT OF GLOBAL SALES)
- FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO THE
U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS)
- FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION,
2019* ($ MILLIONS)
- FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY THERAPEUTIC
AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS)
- FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN
CLINICAL DEVELOPMENT, 2019* (%)
- FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS)
- FIGURE 7 PARTS OF THE BBB
- FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS
- FIGURE 9 METHODS OF CROSSING THE BBB
- FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE, 2014*
(% OF INDUSTRY)
- FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE
COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET)
- FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019
(NUMBER OF UNITS)
